Back to mobile site

Piper Sandler Reiterates Overweight Rating on Verona Pharma (VRNA)

June 27, 2024 9:26 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $36.00 price target on Verona Pharma (NASDAQ: VRNA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login